Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Adjunctive Immune Therapy for Fungal Infections

Arturo Casadevall and Liise-anne Pirofski
Clinical Infectious Diseases
Vol. 33, No. 7 (Oct. 1, 2001), pp. 1048-1056
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4461779
Page Count: 9
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Adjunctive Immune Therapy for Fungal Infections
Preview not available

Abstract

Fungal infections in immunocompromised patients can pose difficult problems in clinical management, because the available antifungal chemotherapy is often unable to eradicate the infection in these people. Hence, the use of immune modulating therapy to augment impaired host immune responses-and thus enhance the efficacy of antifungal drugs-is a reasonable approach to improve the prognosis of fungal infections. Advances in biotechnology have produced a variety of biological response modifiers with the potential to serve as adjunctive immune therapy for the treatment of fungal infections, including cytokines, monoclonal antibodies, and cell growth factors. In recent years, immune-modulating therapies have been studied in an effort to define their potential use for the treatment of fungal infections. Much of the available information on the use of this approach is encouraging and invites further investigation-with the caveats that the information is mostly anecdotal and that immune-modulating therapy occasionally has produced adverse effects.

Page Thumbnails

  • Thumbnail: Page 
1048
    1048
  • Thumbnail: Page 
1049
    1049
  • Thumbnail: Page 
1050
    1050
  • Thumbnail: Page 
1051
    1051
  • Thumbnail: Page 
1052
    1052
  • Thumbnail: Page 
1053
    1053
  • Thumbnail: Page 
1054
    1054
  • Thumbnail: Page 
1055
    1055
  • Thumbnail: Page 
1056
    1056